| DESCRIPTION | - BRINGMANN A. et al., Journal of Biomedicine and Biotechnology, (20100000), vol. 2010 | - |
| DESCRIPTION | - KOBIYAMA et al., Vaccines, (20130000), vol. 1, no. 3, pages 278 - 292 | - |
| OPPOSITION | - Anonymous, "98N12-5 - Item No. 37651 - PRODUCT INFORMATION", Cayman, (20230215), Cayman, URL: https://cdn.caymanchem.com/cdn/seawolf/insert/37651.pdf, XP093296463 | - |
| OPPOSITION | - Anonymous, "Administration of H5N1 Influenza Vaccine ASP7373 Completed in Phase II Clinical Trial", Astellas, (20111111), Astellas, URL: https://www.astellas.com/en/system/files/news/2018-06/111111_en_3.pdf, XP093296465 | - |
| OPPOSITION | - Anonymous, "Administration of Seasonal Flu Vaccine ASP7374 Completed in Phase I/II Clinical", Astellas, (20110915), Astellas, URL: https://www.astellas.com/en/system/files/news/2018-06/110915_4_en.pdf, XP093296468 | - |
| OPPOSITION | - Anonymous, "A revision of the system of nomenclature for influenza viruses: a WHO Memorandum*", Bulletin of the World Health Organization, WHO, (19800121), vol. 58, no. 4, pages 585 - 591, XP093296469 | - |
| OPPOSITION | - Anonymous, "Clinical Review - Fluzone Quadrivalent", FDA, (20130607), FDA, URL: https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Clinical-Review---Fluzone-Quadrivalent.pdf, XP093296459 | - |
| OPPOSITION | - Anonymous, "Flublok (Influenza Vaccine) Sterile Solution for Intramuscular Injection - HIGHLIGHTS OF PRESCRIBING INFORMATION", FDA, (20121201), XP093296497 | - |
| OPPOSITION | - Anonymous, "Moderna Launches New Venture Valera LLC for Infectious Diseases", Moderna, (20150108), Moderna, URL: https://s29.q4cdn.com/435878511/files/doc_news/2015/01/08/moderna-launches-new-venture-valera-llc-infectious-diseases.pdf, XP093296503 | - |
| OPPOSITION | - Anonymous, "U.S. FDA Approves Flublok®, the World's First Recombinant, Highly Puried, EggFree Inuenza Vaccine ", PRNewswire article, (20130116), PRNewswire article, URL: https://www.prnewswire.com/news-releases/us-fda-approves-flublok-the-worlds-first-recombinant-highly-purified-egg-free-influenza-vaccine-187206411.html, XP093296515 | - |
| OPPOSITION | - D37 - Recoding of a change for WO 2013/151663 | - |
| OPPOSITION | - D38 - Form 1200 filed for the parent patent | - |
| OPPOSITION | - D61 - Patentee’s reply to the oppositions of EP3134131 | - |
| OPPOSITION | - D62 - PCT request Form 101 for WO 2013/151663 | - |
| OPPOSITION | - D64 - OD decision following opposition proceedings on EP3134131 | - |
| OPPOSITION | - D74a - Excerpt from 1st International mRNA Health Conference flyer | - |
| OPPOSITION | - De Koker Stefaan, "Type IIFN and mRNA vaccines: an unusual suspect", Universiteit Gent, (20130101), XP093296500 | - |
| OPPOSITION | - Grohskopf Lisa A, Shay David K, Shimabukuro Tom T, Sokolow Leslie Z, Keitel Wendy A, Bresee Joseph S, Cox Nancy J, "Prevention and Control of Seasonal Influenza with Vaccines - Recommendations of the Advisory Committee on Immunization Practices — United States, 2013-2014", Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, Recommendations and Reports, (20130920), vol. 62, no. 7, XP093296526 | - |
| OPPOSITION | - Katalin Kariko, Drew Weissman, "Chapter 13: Impacts of Nucleoside Modification on RNA-Mediated Activation of Toll Like Receptor", Katalin Kariko, Drew Weissman, Shizuo Akira (Editor), Ken J. Ishii (Editor), Nucleic Acids in Innate Immunity, 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA , CRC PRESS-TAYLOR & FRANCIS GROUP , (20080101), pages 179 - 188, ISBN 978-1-4200-6825-2, XP009562574 | - |
| OPPOSITION | - Katalin Kariko et al., "Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: Implication for therapeutic RNA development", Current Opinion in Drug Discovery & Development, (200709), vol. 10, page 5, XP009154595 | - |
| OPPOSITION | - MARTINON F., ET AL., "INDUCTION OF VIRUS-SPECIFIC CYTOTOXIC T LYMPHOCYTES IN VIVO BY LIPOSOME-ENTRAPPED MRNA.", European Journal of Immunology, Wiley-VCH, Hoboken, USA, Hoboken, USA, (19930101), vol. 23., doi:10.1002/eji.1830230749, ISSN 0014-2980, pages 1719 - 1722., XP000618955 | |
| OPPOSITION | - Thomas Kramps, Probst Jochen, "Messenger RNA-based vaccines: progress, challenges, applications", Wiley Interdisciplinary Reviews: RNA, (20130701), vol. 4, doi:10.1002/wrna.1189, ISSN 17577004, pages 737 - 749, XP055180522 | |
| OPPOSITION | - HESS PAUL R ET AL, "Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen", Cancer immunology immunotherapy, Springer, Berlin/Heidelberg, Berlin/Heidelberg , (20060601), vol. 55, no. 6, doi:10.1007/s00262-005-0064-z, ISSN 0340-7004, pages 672 - 683, XP002467278 | |
| OPPOSITION | - Jacob Atsmon; Efrat Kate-Ilovitz; Dimitry Shaikevich; Yossi Singer; Inna Volokhov; Kirsten Y. Haim; Tamar Ben-Yedidia, "Safety and Immunogenicity of Multimeric-001—a Novel Universal Influenza Vaccine", Journal of Clinical Immunology, Kluwer Academic Publishers-Plenum Publishers, Ne, Ne , (20120209), vol. 32, no. 3, doi:10.1007/s10875-011-9632-5, ISSN 1573-2592, pages 595 - 603, XP035054835 | |
| OPPOSITION | - Katherine Houser, Kanta Subbarao, "Influenza Vaccines: Challenges and Solutions", Cell Host & Microbe, Elsevier, NL, NL , (20150301), vol. 17, no. 3, doi:10.1016/j.chom.2015.02.012, ISSN 1931-3128, pages 295 - 300, XP055572607 | |
| OPPOSITION | - Katalin Kariko et al, "Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA", Immunity, (200508), vol. 23, doi:10.1016/j.immuni.2005.06.008, XP055548954 | |
| OPPOSITION | - Karikó K, Buckstein M, Ni H, Weissman D, "Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL , (20050801), vol. 23, no. 2, doi:10.1016/J.IMMUNI.2005.06.008, ISSN 1074-7613, pages 165 - 175, XP002634064 | |
| OPPOSITION | - Bonilla, F.A. ; Oettgen, H.C., "Adaptive immunity", Journal of Allergy and Clinical Immunology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20100201), vol. 125, no. 2, doi:10.1016/j.jaci.2009.09.017, ISSN 0091-6749, pages S33 - S40, XP026914333 | |
| OPPOSITION | - James Heyes et al., "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", Journal of Controlled Release, (20050117), vol. 107, doi:10.1016/j.jconrel.2005.06.014, pages 276 - 287, XP008157522 | |
| OPPOSITION | - Andries Oliwia; Filette Marina De; De Smedt Stefaan C.; Demeester Jo; Poucke Mario Van; Peelman Luc; Sanders Niek N., "Innate immune response and programmed cell death following carrier-mediated delivery of unmodified mRNA to respiratory cells", Journal of Controlled Release, Elsevier, NL, NL , (20130208), vol. 167, no. 2, doi:10.1016/j.jconrel.2013.01.033, ISSN 0168-3659, pages 157 - 166, XP028525413 | |
| OPPOSITION | - Lonez, Bessodes, Scherman, Vandenbranden, Escriou, Ruysschaert, "Cationic lipid nanocarriers activate Toll-like receptor 2 and NLRP3 inflammasome pathways", Nanomedicine: Nanotechnology, Biology, and Medicine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20140501), vol. 10, no. 4, doi:10.1016/j.nano.2013.12.003, ISSN 1549-9634, pages 775 - 782, XP093296573 | |
| OPPOSITION | - Juine-Ruey Chen; Che Ma; Chi-Huey Wong;, "Vaccine design of hemagglutinin glycoprotein against influenza", TRENDS IN BIOTECHNOLOGY., ELSEVIER PUBLICATIONS, CAMBRIDGE., GB, GB , vol. 29, no. 9, doi:10.1016/j.tibtech.2011.04.007, ISSN 0167-7799, pages 426 - 434, XP028383329 | |
| OPPOSITION | - Wang, K. Holtz, K.M. Anderson, K. Chubet, R. Mahmoud, W. Cox, M.M.J., "Expression and purification of an influenza hemagglutinin-one step closer to a recombinant protein-based influenza vaccine", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20060315), vol. 24, no. 12, doi:10.1016/j.vaccine.2005.11.005, ISSN 0264-410X, pages 2176 - 2185, XP005298860 | |
| OPPOSITION | - Ellebedy, A.H. ; Webby, R.J., "Influenza vaccines", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20091105), vol. 27, doi:10.1016/j.vaccine.2009.08.038, ISSN 0264-410X, pages D65 - D68, XP026694007 | |
| OPPOSITION | - Armin Hekele et al., "Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice", Emerging Microbes and Infections, (20130814), vol. 2, doi:10.1038/emi.2013.54, page e52, XP055397456 | |
| OPPOSITION | - Katalin Kariko et al., "Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability ", Molecular Therapy, (200811), vol. 16, no. 11, doi:10.1038/mt.2008.200, pages 1833 - 1840, XP055920956 | |
| OPPOSITION | - Genc Basha, Tatiana I Novobrantseva, Nicole Rosin, Yuen Yi C Tam, Ismail M Hafez, Matthew K Wong, Tsukasa Sugo, Vera M Ruda, June Qin, Boris Klebanov, Marco Ciufolini, Akin Akinc, Ying K Tam, Michael J Hope, Pieter R Cullis, "Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells", Molecular Therapy, No longer published by Elsevier, (20111201), vol. 19, no. 12, doi:10.1038/mt.2011.190, ISSN 15250016, pages 2186 - 2200, XP055024764 | |
| OPPOSITION | - Charlotte Pollard et al., "Type I IFN Counteracts the Induction of Antigen-Specific Immune Responses by Lipid-Based Delivery of mRNA Vaccines", Molecular Therapy, (20130100), vol. 21, no. 1, doi:10.1038/mt.2012.202, pages 251 - 259, XP055378387 | |
| OPPOSITION | - Sean C Semple, Akin Akinc, Jianxin Chen, Ammen P Sandhu, Barbara L Mui, Connie K Cho, Dinah W Y Sah, Derrick Stebbing, Erin J Crosley, Ed Yaworski, et al., "Rational design of cationic lipids for siRNA delivery", Nature Biotechnology, Nature Publishing Group US, New York, New York, (20100201), vol. 28, no. 2, doi:10.1038/NBT.1602, ISSN 1087-0156, pages 172 - 176, XP002633693 | |
| OPPOSITION | - Leuschner Florian, Dutta Partha, Gorbatov Rostic, Novobrantseva Tatiana I, Donahoe Jessica S, Courties Gabriel, Lee Kang Mi, Kim James I, Markmann James F, Marinelli Brett, Panizzi Peter, Lee Won Woo, Iwamoto Yoshiko, Milstein Stuart, Epstein-Barash Hila, Cantley William, Wong Jamie, Cortez-Retamozo Virna, Newton Andita, Love Kevin, Libby Peter, Pittet Mikael J, Swirski Filip K, Koteliansky Victor, Langer Robert, Weissleder Ralph, Anderson Daniel G, Nahrendorf Matthias, "Therapeutic siRNA silencing in inflammatory monocytes in mice", Nature Biotechnology, Nature Publishing Group US, New York, New York, (20111101), vol. 29, no. 11, doi:10.1038/nbt.1989, ISSN 1087-0156, pages 1005 - 1010, XP055920900 | |
| OPPOSITION | - Benjamin Petsch et al., "Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection", Nature Biotechnology, (20121125), vol. 30, doi:10.1038/nbt.2436, page 12, XP055051005 | |
| OPPOSITION | - Andrew J. Geall, Ayush Verma, Gillis R. Otten, Christine A. Shaw, Armin Hekele, Kaustuv Banerjee, Yen Cu, Clayton W. Beard, Luis A. Brito, Thomas Krucker, Derek T. O�Hagan, Manmohan Singh, Peter W. Mason, Nicholas M. Valiante, Philip R. Dormitzer, Susan W. Barnett, Rino Rappuoli, Jeffrey B. Ulmer, Christian W. Mandl, "Nonviral delivery of self-amplifying RNA vaccines.", Proceedings of the National Academy of Sciences (PNAS), National Academy of Sciences, (20120904), vol. 109, no. 36, doi:10.1073/PNAS.1209367109, ISSN 0027-8424, pages 14604 - 14609, XP002683929 | |
| OPPOSITION | - Pardi Norbert, Kariko Katalin, Hogan Michael, Mur- Amatsu Hiromi, Hoxie James A, Weissman Drew, Patil Shilpa, Gadhe Sharda, Sonawane Swapnil, Bansal Manish, Deshpande Suprit, Hermanus Tandile, Morris Lynn, Murugavel K G, Solomon Suniti, Sahay Seema, Paranjape Ramesh, Chakrabarti Bimal K, Bhattacharya Jayanta, "P41.25 Generating an Anti-HIV Vaccine Using Nucleosidemodified mRNA Encoding Envelope", AIDS Research and Human Retrovirus, doi:10.1089/aid.2014.5554.abstract, (20140101), page A249, AIDS Research and Human Retrovirus, URL: https://www.liebertpub.com/doi/epub/10.1089/aid.2014.5554.abstract, XP093296512 | |
| OPPOSITION | - Bart R. Anderson et al., "Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation", Nucleic Acids Research, (20100510), vol. 38, no. 17, doi:10.1093/nar/gkq347, pages 5884 - 5892, XP055041208 | |
| OPPOSITION | - Cox Manon M J; Patriarca Peter A; Treanor John, "FluBlok, a recombinant hemagglutinin influenza vaccine", Influenza and Other Respiratory Viruses, Blackwell Publishing Ltd, UK, UK , (20081101), vol. 2, no. 6, doi:10.1111/j.1750-2659.2008.00053.x, ISSN 1750-2640, pages 211 - 219, XP009132772 | |
| OPPOSITION | - Kelli McKenna, Anne-Sophie Beignon, and Nina Bhardwaj, "Plasmacytoid dendritic cells: linking innate and adaptive immunity.", Journal of Virology, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, US , (20050101), vol. 79, no. 1, doi:10.1128/JVI.79.1.17-27.2005, ISSN 0022-538X, pages 17 - 27, XP002716715 | |
| OPPOSITION | - Taro Kawai, "Antiviral Signaling Through TLRs and RLHs", Taro Kawai, KEN J. ISHII SHIZUO AKIRA, Nucleic Acids in Innate Immunity, CRC Press, (20080522), pages 17 - 29, doi:10.1201/9781420068269-7, ISBN 9780429149870, XP009562573 | |
| OPPOSITION | - Battaglia Luigi, Gallarate Marina, "Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery", Expert Opinion on Drug Delivery, Informa Healthcare, GB, GB , (20120501), vol. 9, no. 5, doi:10.1517/17425247.2012.673278, ISSN 1742-5247, pages 497 - 508, XP093296575 | |
| OPPOSITION | - Raquel P. Deering et al., "Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines", Expert Opinion on Drug Delivery, (20140326), vol. 11, no. 6, doi:10.1517/17425247.2014.901308, pages 885 - 899, XP009183535 | |
| OPPOSITION | - Pascolo Steve, "The messenger's great message for vaccination", EXPERT REVIEW OF VACCINES, FUTURE DRUGS, LONDON, GB, GB , (20150201), vol. 14, no. 2, doi:10.1586/14760584.2015.1000871, ISSN 1476-0584, pages 153 - 156, XP093296528 | |
| OPPOSITION | - Gregory Anthony E., Titball Richard, Williamson Diane, "Vaccine delivery using nanoparticles", Frontiers in Cellular and Infection Microbiology, vol. 3, doi:10.3389/fcimb.2013.00013, XP093042960 | |
| OPPOSITION | - Jiao Chenchen, Wang Bo, Chen Pucheng, Jiang Yongping, Liu Jinxiong, "Analysis of the conserved protective epitopes of hemagglutinin on influenza A viruses", Frontiers in Immunology, Frontiers Media, Lausanne, CH, Lausanne, CH , (20230201), vol. 14, doi:10.3389/fimmu.2023.1086297, ISSN 1664-3224, page 1086297, XP093296577 | |
| OPPOSITION | - SCHLAKE T, THESS A, FOTIN-MLECZEK M, KALLEN K-J, "Developing mRNA-vaccine technologies", RNA BIOLOGY, Taylor & Francis Group, (20121101), vol. 9, no. 11, doi:10.4161/rna.22269, ISSN 1547-6286, pages 1319 - 1330, XP002743467 | |
| SEARCH | - "Influenza A virus (A/Jiangxi/IPB13/2013(H10N8)) segment 4 hemagglutinin (HA) gene, complete cds.", GENBANK, (20140612), Database accession no. KJ406543, URL: http://www.ncbi.nlm.nih.gov/nuccore/KJ406543, XP055232578 [AP] 1-15 * the whole document * | - |
| SEARCH | - ARMIN HEKELE ET AL, "Rapidly produced SAM? vaccine against H7N9 influenza is immunogenic in mice", EMERGING MICROBES & INFECTIONS, (20130801), vol. 2, no. 8, doi:10.1038/emi.2013.54, page e52, XP055397456 [X] 1,2,5-12,14,15 * Abstract;p. 2 "LNP/RNA f0ormulation" * [Y] 1-15 | |
| SEARCH | - BENJAMIN PETSCH ET AL, "Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection", NATURE BIOTECHNOLOGY, (20120101), vol. 30, no. 12, doi:10.1038/nbt.2436, ISSN 1087-0156, pages 1210 - 1216, XP055051005 [Y] 1-15 * Abstract * | |
| SEARCH | - ANDREW J GEALL ET AL, "Nonviral delivery of self-amplifying RNA vaccines", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, NATIONAL ACADEMY OF SCIENCES, US, vol. 109, no. 36, doi:10.1073/PNAS.1209367109, ISSN 0027-8424, (20120904), pages 14604 - 14609, (20120820), XP002683929 [Y] 1-15 * Abstract; p. 14608 "LNP/RNA formulation" * | |
